|
1
|
Shigematsu H and Gazdar AF: Somatic
mutations of epidermal growth factor receptor signaling pathway in
lung cancers. Int J Cancer. 118:257–262. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhou C and Yao LD: Strategies to improve
outcomes of patients with EGRF-mutant non-small cell lung cancer:
Review of the literature. J Thorac Oncol. 11:174–186. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ohashi K, Maruvka YE, Michor F and Pao W:
Epidermal growth factor receptor tyrosine kinase
inhibitor-resistant disease. J Clin Oncol. 31:1070–1080. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Remon J, Steuer CE, Ramalingam SS and
Felip E: Osimertinib and other third-generation EGFR TKI in
EGFR-mutant NSCLC patients. Ann Oncol. 29 (Suppl 1):i20–i27. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang Z, Yang N, Ou Q, Xiang Y, Jiang T, Wu
X, Bao H, Tong X, Wang X, Shao YW, et al: Investigating novel
resistance mechanisms to third-generation EGFR tyrosine kinase
inhibitor osimertinib in non-small cell lung cancer patients. Clin
Cancer Res. 24:3097–3107. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang H, Zhao PJ, Su D, Feng J and Ma SL:
Paris saponin I induces apoptosis via increasing the Bax/Bcl-2
ratio and caspase-3 expression in gefitinib-resistant non-small
cell lung cancer in vitro and in vivo. Mol Med Rep. 9:2265–2272.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang H, Zhao P, Feng J, Su D and Ma S:
Effect of Paris saponin I on radiosensitivity in a
gefitinib-resistant lung adenocarcinoma cell line. Oncol Lett.
7:2059–2064. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao P, Jiang H, Su D, Feng J, Ma S and
Zhu X: Inhibition of cell proliferation by mild hyperthermia at
43°C with Paris saponin I in the lung adenocarcinoma cell line
PC-9. Mol Med Rep. 11:327–332. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu X, Jiang H, Li J, Xu J and Fei Z:
Anticancer effects of Paris saponins by apoptosis and PI3K/AKT
pathway in gefitinib-resistant non-small cell lung cancer. Med Sci
Monit. 22:1435–1441. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao PJ, Song SC, Du LW, Zhou GH, Ma SL,
Li JH, Feng JG, Zhu XH and Jiang H: Paris Saponins enhance
radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell
line by inducing apoptosis and G2/M cell cycle phase arrest. Mol
Med Rep. 13:2878–2884. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song S, Du L, Jiang H, Zhu X, Li J and Xu
J: Paris Saponin I sensitizes gastric cancer cell lines to
cisplatin via cell cycle arrest and apoptosis. Med Sci Monit.
22:3798–3803. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zheng R, Rao Y, Jiang H, Liu X, Zhu X, Li
J and Xu J: Therapeutic potential of ginsenoside Rg3 via inhibiting
Notch/HES1 pathway in lung cancer cells. Transl Cancer Res.
5:464–469. 2016. View Article : Google Scholar
|
|
15
|
Zheng R, Jiang H, Li J, Liu X and Xu H:
Polyphyllin II restores sensitization of the resistance of PC-9/ZD
cells to gefitinib by a negative regulation of the PI3K/Akt/mTOR
signaling pathway. Curr Cancer Drug Targets. 17:376–385. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang H, Fei Z and Jiang H: Polyphyllin VII
increases sensitivity to gefitinib by modulating the elevation of
P21 in acquired gefitinib resistant non-small cell lung cancer. J
Pharmacol Sci. 134:190–196. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang Q, Chen W, Xu Y, Lv X, Zhang M and
Jiang H: Polyphyllin I modulates MALAT1/STAT3 signaling to induce
apoptosis in gefitinib-resistant non-small cell lung cancer.
Toxicol Appl Pharmacol. 356:1–7. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hong F, Gu W, Jiang J, Liu X and Jiang H:
Anticancer activity of polyphyllin I in nasopharyngeal carcinoma by
modulation of lncRNA ROR and P53 signalling. J Drug Target.
27:806–811. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang Y, Tantai J, Sun Y, Zhong C and Li Z:
Effect of hyperoside on the apoptosis of A549 human non-small cell
lung cancer cells and the underlying mechanism. Mol Med Rep.
16:6483–6488. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guon TE and Chung HS: Hyperoside and rutin
of Nelumbo nucifera induce mitochondrial apoptosis through a
caspase- dependent mechanism in HT-29 human colon cancer cells.
Oncol Lett. 11:2463–2470. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Boukes GJ and van de Venter M: The
apoptotic and autophagic properties of two natural occurring
prodrugs, hyperoside and hypoxoside, against pancreatic cancer cell
lines. Biomed Pharmacother. 83:617–626. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu X, Ji M, Han Y, Guo Y, Zhu W, Gao F,
Yang X and Zhang C: PGRMC1-dependent autophagy by hyperoside
induces apoptosis and sensitizes ovarian cancer cells to cisplatin
treatment. Int J Oncol. 50:835–846. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li W, Liu M, Xu YF, Feng Y, Che JP, Wang
GC and Zheng JH: Combination of quercetin and hyperoside has
anticancer effects on renal cancer cells through inhibition of
oncogenic microRNA-27a. Oncol Rep. 31:117–124. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang FQ, Liu M, Li W, Che JP, Wang GC and
Zheng JH: Combination of quercetin and hyperoside inhibits prostate
cancer cell growth and metastasis via regulation of microRNA-21.
Mol Med Rep. 11:1085–1092. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang N, Ying MD, Wu YP, Zhou ZH, Ye ZM,
Li H and Lin DS: Hyperoside, a flavonoid compound, inhibits
proliferation and stimulates osteogenic differentiation of human
osteosarcoma cells. PLoS One. 9:e989732014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li JP, Liao XH, Xiang Y, Yao A, Song RH,
Zhang ZJ, Huang F, Dai ZT and Zhang TC: Hyperoside and let-7a-5p
synergistically inhibits lung cancer cell proliferation via
inducing G1/S phase arrest. Gene. 679:232–240. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fu T, Wang L, Jin XN, Sui HJ, Liu Z and
Jin Y: Hyperoside induces both autophagy and apoptosis in non-small
cell lung cancer cells in vitro. Acta Pharmacol Sin. 37:505–518.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu YH, Liu GH, Mei JJ and Wang J: The
preventive effects of hyperoside on lung cancer in vitro by
inducing apoptosis and inhibiting proliferation through Caspase-3
and P53 signaling pathway. Biomed Pharmacother. 83:381–391. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lü P: Inhibitory effects of hyperoside on
lung cancer by inducing apoptosis and suppressing inflammatory
response via caspase-3 and NF-κB signaling pathway. Biomed
Pharmacother. 82:216–225. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xing YQ, Li A, Yang Y, Li XX, Zhang LN and
Guo HC: The regulation of FOXO1 and its role in disease
progression. Life Sci. 193:124–131. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cosimo E, Tarafdar A, Moles MW, Holroyd
AK, Malik N, Catherwood MA, Hay J, Dunn KM, Macdonald AM, Guichard
SM, et al: AKT/mTORC2 inhibition activates FOXO1 function in CLL
cells reducing B-cell receptor-mediated survival. Clin Cancer Res.
25:1574–1587. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guo X and Hua Y: CCAT1: An oncogenic long
noncoding RNA in human cancers. J Cancer Res Clin Oncol.
143:555–562. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin H, Cheng W, Yan H and Zhang X:
Overexpression of the long noncoding RNA CCAT1 promotes metastasis
via epithelial-to-mesenchymal transition in lung adenocarcinoma.
Oncol Lett. 16:1809–1814. 2018.PubMed/NCBI
|
|
35
|
Hu B, Zhang H, Wang Z, Zhang F, Wei H and
Li L: LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance
in non-small-cell lung cancer cell line by targeting SOX4. Cancer
Biol Ther. 18:974–983. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen J, Zhang K, Song H, Wang R, Chu X and
Chen L: Long noncoding RNA CCAT1 acts as an oncogene and promotes
chemoresistance in docetaxel-resistant lung adenocarcinoma cells.
Oncotarget. 7:62474–62489. 2016.PubMed/NCBI
|
